Structure‐Based Virtual Screening for Dopamine D2 Receptor Ligands as Potential Antipsychotics

Structure‐based virtual screening using a D2 receptor homology model was performed to identify dopamine D2 receptor ligands as potential antipsychotics. From screening a library of 6.5 million compounds, 21 were selected and were subjected to experimental validation. From these 21 compounds tested, ten D2 ligands were identified (47.6 % success rate, among them D2 receptor antagonists, as expected) that have additional affinity for other receptors tested, in particular 5‐HT2A receptors. The affinity (Ki values) of the compounds ranged from 58 nm to about 24 μm. Similarity and fragment analysis indicated a significant degree of structural novelty among the identified compounds. We found one D2 receptor antagonist that did not have a protonatable nitrogen atom, which is a key structural element of the classical D2 pharmacophore model necessary for interaction with the conserved Asp(3.32) residue. This compound exhibited greater than 20‐fold binding selectivity for the D2 receptor over the D3 receptor. We provide additional evidence that the amide hydrogen atom of this compound forms a hydrogen bond with Asp(3.32), as determined by tests of its derivatives that cannot maintain this interaction.

[1]  Andreas Evers,et al.  Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. , 2005, Journal of medicinal chemistry.

[2]  P. Conn,et al.  Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. , 2012, Discovery medicine.

[3]  Brian K Shoichet,et al.  Structure-based drug screening for G-protein-coupled receptors. , 2012, Trends in pharmacological sciences.

[4]  Mark A. Murcko,et al.  Virtual screening : an overview , 1998 .

[5]  Chris de Graaf,et al.  Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A β-Adrenoceptor Case Study , 2015, J. Chem. Inf. Model..

[6]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[7]  J. Soares,et al.  Atypical antipsychotics and mood stabilization in bipolar disorder , 2003, Psychopharmacology.

[8]  P. Robledo,et al.  QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine , 2006, Neuropharmacology.

[9]  Shaomeng Wang,et al.  Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D3 Receptor Antagonists , 2014, Journal of medicinal chemistry.

[10]  H. Hartung,et al.  Mitoxantrone (Novantrone®) in multiple sclerosis: new insights , 2004, Expert review of neurotherapeutics.

[11]  M. Rowley,et al.  Current and novel approaches to the drug treatment of schizophrenia. , 2001, Journal of medicinal chemistry.

[12]  Marcin Feder,et al.  Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening , 2013, J. Chem. Inf. Model..

[13]  W. Patrick Walters,et al.  A guide to drug discovery: Designing screens: how to make your hits a hit , 2003, Nature Reviews Drug Discovery.

[14]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[15]  S. Leucht,et al.  Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective , 2014, Evidence-Based Mental Health.

[16]  A. Taly Novel approaches to drug design for the treatment of schizophrenia , 2013, Expert opinion on drug discovery.

[17]  Yi-Ping Phoebe Chen,et al.  A steered molecular dynamics mediated hit discovery for histone deacetylases. , 2014, Physical chemistry chemical physics : PCCP.

[18]  H. Meltzer Update on typical and atypical antipsychotic drugs. , 2013, Annual review of medicine.

[19]  F. Sanz,et al.  Novel insights on the structural determinants of clozapine and olanzapine multi-target binding profiles. , 2014, European journal of medicinal chemistry.

[20]  H. Stark,et al.  Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. , 2009, Bioorganic & medicinal chemistry letters.

[21]  G. Schneider,et al.  From Virtual to Real Screening for D3 Dopamine Receptor Ligands , 2005, Chembiochem : a European journal of chemical biology.

[22]  Peter Kolb,et al.  Limits of Ligand Selectivity from Docking to Models: In Silico Screening for A1 Adenosine Receptor Antagonists , 2012, PloS one.

[23]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[24]  T. Suppes,et al.  Treatment of bipolar mania with atypical antipsychotics , 2004, Expert review of neurotherapeutics.

[25]  Mercedes K. Taylor,et al.  Discovery, Optimization, and Characterization of Novel D2 Dopamine Receptor Selective Antagonists , 2014, Journal of medicinal chemistry.

[26]  Chunyan Tan,et al.  A Two-Step Target Binding and Selectivity Support Vector Machines Approach for Virtual Screening of Dopamine Receptor Subtype-Selective Ligands , 2012, PloS one.

[27]  H. Senderowitz,et al.  G Protein-Coupled Receptors: target-based in silico screening. , 2009, Current pharmaceutical design.

[28]  Michael M. Mysinger,et al.  Structure-based ligand discovery for the protein–protein interface of chemokine receptor CXCR4 , 2012, Proceedings of the National Academy of Sciences.

[29]  Avner Schlessinger,et al.  Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.

[30]  F. López-Muñoz,et al.  Neurobiological Background for the Development of New Drugs in Schizophrenia , 2011, Clinical neuropharmacology.

[31]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[32]  Subramaniam Ananthan,et al.  Recent Advances in Structure-Based Virtual Screening of G-Protein Coupled Receptors , 2009, The AAPS Journal.

[33]  Sarah A. Scott,et al.  Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. , 2009, Bioorganic & medicinal chemistry letters.

[34]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[35]  Chris de Graaf,et al.  From heptahelical bundle to hits from the Haystack: structure-based virtual screening for GPCR ligands. , 2013, Methods in enzymology.

[36]  B. Roth,et al.  Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. , 2008, Bioorganic & medicinal chemistry.

[37]  A. Sali,et al.  Statistical potential for assessment and prediction of protein structures , 2006, Protein science : a publication of the Protein Society.

[38]  Ruben Abagyan,et al.  Structure-Based Ligand Discovery Targeting Orthosteric and Allosteric Pockets of Dopamine Receptors , 2013, Molecular Pharmacology.

[39]  S. Salomone,et al.  Homology Modeling of Dopamine D2 and D3 Receptors: Molecular Dynamics Refinement and Docking Evaluation , 2012, PloS one.

[40]  Peter Kolb,et al.  Identifying modulators of CXC receptors 3 and 4 with tailored selectivity using multi-target docking. , 2015, ACS chemical biology.

[41]  Markus Lill,et al.  Virtual screening in drug design. , 2013, Methods in molecular biology.

[42]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[43]  R. Stevens,et al.  Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.

[44]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[45]  Ferran Sanz,et al.  New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones. , 2002, Journal of medicinal chemistry.

[46]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.